App-Quantinova.ai

Effects of equivalent weight loss, with or without exercise, on sex hormones related to breast cancer risk in postmenopausal women: The SHAPE-2 trial.

Anne Maria May - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Alora

Effect of weight loss intervention on inflammatory and metabolic markers in breast cancer survivors: The lifestyle, exercise, and nutrition (LEAN) study.

Erikka Loftfield - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Patient-reported outcomes and behavioral risk factors as predictors of chemoprevention adherence among women in the National Surgical Adjuvant Breast and Bowel Program (NSABP) Breast Cancer Prevention P-1 trial.

Stephanie R. Land - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Effect of exercise and dietary fish consumption on risk of recurrence in colon cancer: A multinational study.

Mohammed Shaik - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Solid malignancies

N/A

Cancer screening behaviors among spouses in a nationally representative sample.

Ashwin A Kotwal - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Identfying barriers to providing tobacco cessation support for cancer patients.

James Roger Marshall - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Incidence of colorectal neoplasia in a high-risk population screened for colorectal cancer: Result of five consecutive mass screening campaigns in a well-defined population.

Sylvain Manfredi - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Death less than one month from diagnosis in children with cancer: A population-based analysis.

Adam L. Green - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Impact of antibiotic exposure on the risk of colorectal cancer.

Shimon Ben Boursi - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Association of diabetes and cancer-diagnoses in primary care practices in Germany.

Nina Schmidt - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The decrease in global cancer mortality.

Paolo Boffetta - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Differences in clinical characteristics and overall survival in never-smokers with lung squamous cell carcinoma.

Wanling Zeng - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Risk factors for atypical femur fractures in cancer patients.

Beatrice J. Edwards - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Spectrum of HIV/AIDS-associated cancers in south India.

Shruti Prem - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Solid malignancies

N/A

Features of adult clinical trial participants with glioblastoma (GB) at The University of Texas MD Anderson Cancer Center (MDACC).

Mark Daniel Anderson - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

PC or PCV? That is the question: A retrospective review of primary anaplastic oligodendroglial tumors treated with procarbazine and CCNU without or with vincristine.

Courtney C. Webre - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

procarbazine

REBECA: A phase I study of bevacizumab (BEV) and whole-brain radiation therapy (WBRT) for treatment of solid tumors brain metastases (BM), EudraCT: 2009-015977-11.

Christelle Levy - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Bevacizumab

Targetable signaling pathway mutations and progression of IDH-mutant glioma.

Hiroaki Wakimoto - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Application of a validated predictive model for venous thrombo-embolism in cancer to patients with glioblastoma.

Ajay Prakash Abad - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Effect of inhibition of ?-secretase activity on cleavage of p75 neurotrophin receptor (p75NTR) and proliferation of brain tumor initiating cells (BTICs) and malignant gliomas (MGs).

Rajappa Kenchappa - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts